ArticleInternational journal of ophthalmology2025
Dexamethasone intravitreal implant monotherapy in naive patients with macular edema secondary to retinal vein occlusion: long term follow-up retrospective cohort study.
Article in International journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Direct randomized evidence comparing ranibizumab and bevacizumab for macular edema secondary to retinal vein occlusion: a systematic review and meta-analysis.BMC ophthalmology · 2026Pooled it
- Safety and efficacy of ranibizumab combined with dexamethasone intravitreal implant versus ranibizumab monotherapy for macular edema secondary to retinal vein occlusion: a 12-month prospective, randomized study.International ophthalmology · 2025Trial
- Jueling Mingmu decoction combined with ranibizumab for retinal vein occlusion induced macular edema: A randomized controlled clinical trial.International ophthalmology · 2025Trial
- Efficacy and Safety of Ranibizumab Combined with Dexamethasone Intravitreal Implant Sequential Therapy for Macular Edema Secondary to Non-Ischemic Retinal Vein Occlusion.Drug design, development and therapy · 2026Article
- Efficacy and Safety of Intravitreal Triamcinolone Acetonide Alone or Combined with Intravitreal Bevacizumab in the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion.Beyoglu eye journal · 2026Article
- Effect of intravitreal injection of dexamethasone implant on the corneal morphology of young adults with central retinal vein occlusion.International journal of ophthalmology · 2026Article
- Real-life short-term experience of switching from other anti-VEGF therapy to faricimab in patients with refractory macular edema secondary to retinal vein occlusion in China.International ophthalmology · 2025Article
- Integration of peripheral blood-based systemic inflammatory indices and retinal imaging using interpretable machine learning for predicting anti-VEGF treatment response in macular edema secondary to retinal vein occlusion.Frontiers in cell and developmental biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the efficacy and safety of repeated dexamethasone implants with real-life data in eyes with naive retinal vein occlusion (RVO) with macular edema (ME) at a minimum of 60mo follow-up.
methodsIn this retrospective cohort study, the data about best corrected visual acuity (BCVA), central macular thickness (CMT), serous macular detachment (SMD), hard exudate, hyperreflective foci (HRF), cystoid degeneration, pearl necklace sign, epiretinal membrane (ERM), disorganization of retinal inner layers (DRIL), ellipsoid zone and external limiting membrane (EZ-ELM) integrity, intraocular pressure (IOP) and lens condition were recorded.
resultsThirty-eight eyes of 38 patients were included in the study. Thirteen patients presented with central RVO (CRVO) and 25 with branch RVO (BRVO). The mean follow-up time was 69.9±15.8mo, and the mean number of injections was 7.9±4.0. The mean BCVA gain was 25.0±36 letters, and this difference was statistically significant (
conclusionIntravitreal dexamethasone monotherapy is an effective and safe treatment option for the treatment-naive RVO-ME patients in the long-term follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.